These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 21225122

  • 41. [Botulinum toxin therapy for focal dystonia].
    Hahn K, Niklai E, Garzuly F, Szupera Z.
    Orv Hetil; 2009 Jul 19; 150(29):1381-4. PubMed ID: 19581172
    [Abstract] [Full Text] [Related]

  • 42. Botulinum toxin injection and tear production.
    Alsuhaibani AH, Eid SA.
    Curr Opin Ophthalmol; 2018 Sep 19; 29(5):428-433. PubMed ID: 29994851
    [Abstract] [Full Text] [Related]

  • 43. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
    Gill HS, Kraft SP.
    Can J Neurol Sci; 2010 Sep 19; 37(5):631-6. PubMed ID: 21059510
    [Abstract] [Full Text] [Related]

  • 44. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S, Susel Z, Honigman S.
    Isr Med Assoc J; 2008 Jul 19; 10(7):520-2. PubMed ID: 18751631
    [Abstract] [Full Text] [Related]

  • 45. Effect of eyelid botulinum toxin injection on lacrimal drainage.
    Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G.
    Am J Ophthalmol; 2000 Apr 19; 129(4):481-6. PubMed ID: 10764857
    [Abstract] [Full Text] [Related]

  • 46. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
    Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS.
    Eur J Ophthalmol; 2014 Apr 19; 24(6):830-4. PubMed ID: 24803156
    [Abstract] [Full Text] [Related]

  • 47. Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.
    Maneksha V, Chakrabarty S, Tanwar M, Pillai MR.
    Indian J Ophthalmol; 2021 Oct 19; 69(10):2777-2781. PubMed ID: 34571634
    [Abstract] [Full Text] [Related]

  • 48. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
    Chang LB, Tsai CP, Liao KK, Kao KP, Yuan CL, Yen DJ, Lin KP.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jan 19; 62(1):1-5. PubMed ID: 10063705
    [Abstract] [Full Text] [Related]

  • 49. Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm.
    Hast MA, Kong AM, Desai S, Back S, Syed S, Holmes J.
    Toxins (Basel); 2024 Aug 16; 16(8):. PubMed ID: 39195772
    [Abstract] [Full Text] [Related]

  • 50. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ, Shen JH, Chen Y, Lian YJ.
    Turk Neurosurg; 2011 Aug 16; 21(4):625-9. PubMed ID: 22194126
    [Abstract] [Full Text] [Related]

  • 51. A comparison of facial muscle squeezing versus non-facial muscle squeezing on the efficacy of botulinumtoxin-A injections for the treatment of facial dystonia.
    O' Reilly P, Ross J, Norris J, Malhotra R.
    Orbit; 2012 Dec 16; 31(6):400-3. PubMed ID: 23061606
    [Abstract] [Full Text] [Related]

  • 52. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
    Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F.
    J Neurol; 2002 Jan 16; 249(1):64-8. PubMed ID: 11954870
    [Abstract] [Full Text] [Related]

  • 53. Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.
    Poonyathalang A, Preechawat P, Jamnansiri U.
    Jpn J Ophthalmol; 2005 Jan 16; 49(4):327-8. PubMed ID: 16075337
    [No Abstract] [Full Text] [Related]

  • 54. Evaluating Headache Incidence and Characteristics After Botulinum Toxin Treatment in Blepharospasm and Hemifacial Spasm Patients: A Retrospective Cohort Clinical Study.
    Bilgin S, Ozdemir KT, Yaka EC, Demir Ö, Aydın H, Şener U.
    Clin Neuropharmacol; 2005 Jan 16; 47(5):157-162. PubMed ID: 39258549
    [Abstract] [Full Text] [Related]

  • 55. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS, MacKenzie KR, Cook AE, Leatherbarrow B.
    Clin Exp Ophthalmol; 2010 Oct 16; 38(7):688-91. PubMed ID: 20456439
    [Abstract] [Full Text] [Related]

  • 56. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P, Choolam A, Kulkantrakorn K.
    Neurol Sci; 2017 Nov 16; 38(11):2031-2036. PubMed ID: 28884242
    [Abstract] [Full Text] [Related]

  • 57. [What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?].
    Roggenkämper P.
    Ophthalmologe; 2007 Sep 16; 104(9):763-6. PubMed ID: 17726608
    [Abstract] [Full Text] [Related]

  • 58. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG, Tyrrell EG, Grosset KA.
    J Rehabil Med; 2015 Feb 16; 47(2):183-6. PubMed ID: 25325305
    [Abstract] [Full Text] [Related]

  • 59. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK.
    Singapore Med J; 1998 Sep 16; 39(9):403-5. PubMed ID: 9885719
    [Abstract] [Full Text] [Related]

  • 60. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
    Kenney C, Jankovic J.
    J Neural Transm (Vienna); 2008 Sep 16; 115(4):585-91. PubMed ID: 17558461
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.